Press Releases

Press Releases

Date	Title
Jun 05, 2023	Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference
May 20, 2023	Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
May 04, 2023	Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
May 03, 2023	Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference
May 03, 2023	Alnylam Issues 2022 Corporate Responsibility Report
Apr 26, 2023	Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Apr 20, 2023	Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results
Mar 08, 2023	Alnylam Announces Appointment of Peter Kellogg to Board of Directors
Mar 01, 2023	Alnylam to Webcast Presentations at Upcoming March Investor Conferences
Feb 23, 2023	Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity

For Media Inquiries, please contact:

Christine Lindenboom

SVP, Investor Relations & Corporate Communications media@alnylam.com 617-682-4340

For Investor Inquiries, please contact:

Josh Brodsky

VP, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276

MEDIA KIT

Essential assets and documents related to Alnylam

Looking for specific information that isn't listed above?